Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Rating of “Moderate Buy” by Brokerages

Cardiff Oncology, Inc. (NASDAQ:CRDF) has earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $10.6250.

Several analysts have issued reports on the company. HC Wainwright dropped their price target on Cardiff Oncology from $18.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, October 8th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CRDF. Blair William & Co. IL grew its holdings in Cardiff Oncology by 521.0% during the first quarter. Blair William & Co. IL now owns 1,751,274 shares of the company’s stock worth $5,499,000 after purchasing an additional 1,469,249 shares during the period. Nuveen LLC acquired a new position in shares of Cardiff Oncology during the 1st quarter worth approximately $2,693,000. Laurion Capital Management LP raised its stake in Cardiff Oncology by 37.2% in the 3rd quarter. Laurion Capital Management LP now owns 2,465,872 shares of the company’s stock valued at $5,080,000 after acquiring an additional 668,590 shares during the period. Acorn Capital Advisors LLC lifted its holdings in Cardiff Oncology by 39.3% during the 3rd quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock valued at $4,042,000 after purchasing an additional 553,317 shares during the last quarter. Finally, Flputnam Investment Management Co. boosted its position in Cardiff Oncology by 1,008.8% during the third quarter. Flputnam Investment Management Co. now owns 597,233 shares of the company’s stock worth $1,230,000 after purchasing an additional 543,370 shares during the period. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Cardiff Oncology Trading Up 3.6%

Shares of NASDAQ CRDF traded up $0.07 during mid-day trading on Friday, reaching $2.03. 1,234,453 shares of the company’s stock were exchanged, compared to its average volume of 763,901. Cardiff Oncology has a twelve month low of $1.90 and a twelve month high of $5.64. The firm has a market capitalization of $136.74 million, a price-to-earnings ratio of -2.57 and a beta of 1.68. The business has a fifty day simple moving average of $2.17 and a 200 day simple moving average of $2.74.

Cardiff Oncology (NASDAQ:CRDF) last posted its earnings results on Thursday, November 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.03. Cardiff Oncology had a negative return on equity of 77.21% and a negative net margin of 10,064.27%.The business had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.12 million. Equities research analysts predict that Cardiff Oncology will post -0.99 earnings per share for the current fiscal year.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.